Drug Profile
Lemborexant - Eisai
Alternative Names: DAYVIGO; DAYVIGOTM; E-2006; LEM - EisaiLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Eisai Inc
- Class Amides; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Insomnia
- Phase II Circadian rhythm sleep disorders
- No development reported Chronic obstructive pulmonary disease; Sleep apnoea syndrome
Most Recent Events
- 01 Feb 2024 Eisai plans to launch lemborexant for Insomnia in South Africa (PO) in June 2024
- 28 Jan 2024 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In the elderly, In adults) in USA (PO, Tablet)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Sleep-apnoea-syndrome(In the elderly, In adults) in USA (PO, Tablet)